Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | PIM1 | P11309 | 7/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925800 | 1.00 | AXL (0.41) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL29925447 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL27031805 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL27031824 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL29925747 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL29925683 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL27031746 | 0.89 | PIM1 (0.38) | AXLPIM1MAP2K4PIM2LRRK2 | |
| SCHEMBL29925051 | 0.84 | LRRK2 (0.38) | MAP2K4LRRK2DYRK1A | |
| SCHEMBL29925270 | 0.84 | LRRK2 (0.38) | MAP2K4LRRK2DYRK1A | |
| SCHEMBL29925297 | 0.84 | LRRK2 (0.38) | MAP2K4LRRK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | AXL 1898/4885PIM1 735/4885MAP2K4 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.